A novel therapeutic target for preventing Helicobacter pylori-associated diseases

预防幽门螺杆菌相关疾病的新治疗靶点

• 批准号: nhmrc : GNT1123357
• 负责人: Dr Trevelyan Menheniott
• 金额: $ 75.03万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-therapeutic-target-associated-diseases/1347340
• 关键词: novel; therapeutic; target; preventing; Helicobacter

Gastric cancer mainly results from chronic inflammation (gastritis) caused by the stomach-dwelling bacterium, Helicobacter pylori. We have identified a potassium channel which our data suggest could be a new therapeutic target for protecting against gastric cancer caused by H. pylori infection. This project will test the role of this channel in H. pylori gastritis and see whether drugs that target this channel can protect mice against H. pylori-associated disease.

胃癌主要由胃内细菌幽门螺杆菌引起的慢性炎症（胃炎）引起。我们已经确定了一个钾通道，我们的数据表明，这可能是一个新的治疗靶点，以防止由H。幽门感染这个项目将测试这个通道在H. pylori胃炎，看看针对这一通道的药物是否可以保护小鼠免受H。幽门相关疾病